In June 2008, the HE4 enzyme immunoassay (EIA) test kit (Fujirebio Diagnostics, Sweden) and, in March 2010, the ARCHITECT HE4 automated version (Abbott Diagnostics, UK) were approved by the FDA as substantially equivalent to a MUC16 assay for ovarian cancer. Here, MUC16 is linked to ovarian carcinoma.